A Research Study in Italy to Understand How the Dose Check App Used With Xultophy® Works in the Treatment of People Living With Type 2 Diabetes
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Withdrawn
Study type
Observational
Enrollment
0actual
Sites
19
Country
Italy
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study has been cancelled due to the study's rejection from the local Italian ethics Committee
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-07 | estimated | When the study began enrolling |
| Primary completion | 2025-02-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-02 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-10-01 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 2
Intervention
- Drug: IDegLira — also filed as Xultophy
Primary outcome
what the primary-completion date above is the date OFParticipant downloaded and actively used the app (Yes/No)
measured From baseline (week 0) to end of the study (EOS) visit (week 26)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed